| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911077 | Lung Cancer | 2015 | 4 Pages |
Abstract
BM are frequent in advanced EGFR-mutated or ALK-rearranged NSCLCs, with an estimated >45% of patients with CNS involvement by three years of survival with the use of targeted therapies. These data point toward the CNS as an important unmet clinical need in the evolving schema for personalized care in NSCLC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Deepa Rangachari, Norihiro Yamaguchi, Paul A. VanderLaan, Erik Folch, Anand Mahadevan, Scott R. Floyd, Erik J. Uhlmann, Eric T. Wong, Suzanne E. Dahlberg, Mark S. Huberman, Daniel B. Costa,